Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Journal of Epidemiology Année : 2023

Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis

1 Nuffield Department of Population Health [Oxford]
2 CIRC - IARC - Centre International de Recherche contre le Cancer - International Agency for Research on Cancer
3 University of Bristol [Bristol]
4 Imperial College London
5 NCI-NIH - National Cancer Institute [Bethesda]
6 CIBERESP - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health
7 RIVM - National Institute for Public Health and the Environment [Bilthoven]
8 EREN [CRESS - U1153 / UMR_A 1125] - Nutritional Epidemiology Research Team | Equipe de Recherche en Epidémiologie Nutritionnelle
9 NIA - National Institute on Aging [Bethesda, USA]
10 UWA - The University of Western Australia
11 Melbourne School of Population and Global Health [Melbourne]
12 Harvard T.H. Chan School of Public Health
13 Keck School of Medicine [Los Angeles]
14 DKFZ - German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
15 Hiroshima University
16 University of Hawaii
17 FIHW - Finnish Institute for Health and Welfare
18 UTHSC - The University of Tennessee Health Science Center [Memphis]
19 Aarhus University Hospital
20 RERF - Radiation Effects Research Foundation [Hiroshima City, Japan]
21 Johns Hopkins Bloomberg School of Public Health [Baltimore]
22 McGill University = Université McGill [Montréal, Canada]
23 Erasmus MC - Erasmus University Medical Center [Rotterdam]
24 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
25 Uppsala Universitet [Uppsala]
26 Hokkaido University [Sapporo, Japan]
27 Umeå University, Sweden
28 MSKCC - Memorial Sloan Kettering Cancer Center
29 UC San Francisco - University of California [San Francisco]
Barbara Cohn
  • Fonction : Auteur
Leon Flicker
Jiaqi Huang
Wen-Yi Huang
Kazuya Mikami
  • Fonction : Auteur
Anja Olsen
Domenico Palli
  • Fonction : Auteur
Catherine Schaefer
  • Fonction : Auteur
Pär Stattin
Rosalind Eeles
  • Fonction : Auteur
Christopher Haiman
  • Fonction : Auteur
Zsofia Kote-Jarai
  • Fonction : Auteur
Fredrick Schumacher
  • Fonction : Auteur
Sara Benlloch
  • Fonction : Auteur
Ali Amin Al Olama
  • Fonction : Auteur
Kenneth Muir
  • Fonction : Auteur
Sonja Berndt
  • Fonction : Auteur
David Conti
  • Fonction : Auteur
Fredrik Wiklund
  • Fonction : Auteur
Stephen Chanock
  • Fonction : Auteur
Ying Wang
  • Fonction : Auteur
Catherine Tangen
  • Fonction : Auteur
Jyotsna Batra
  • Fonction : Auteur
Judith Clements
  • Fonction : Auteur
Naomi Allen
  • Fonction : Auteur
Timothy Key
  • Fonction : Auteur
Ruth Travis
  • Fonction : Auteur

Résumé

Abstract Background Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer. Methods Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium. Results In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I. Conclusions These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.
Fichier principal
Vignette du fichier
dyac124.pdf (1.29 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04454915 , version 1 (23-04-2024)

Identifiants

Citer

Eleanor Watts, Aurora Perez-Cornago, Georgina Fensom, Karl Smith-Byrne, Urwah Noor, et al.. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. International Journal of Epidemiology, 2023, 52 (1), pp.71-86. ⟨10.1093/ije/dyac124⟩. ⟨hal-04454915⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More